Acquired TTP and Septic Disseminated Intravascular Coagulation Distinguishable With Lab Tests
Severe thrombocytopenia, antithrombin levels, and degree of fibrinogen degradation product elevation were found to be distinguishing factors of aTTP.
Diagnosis & Disease Information
Emotional, Cognitive Issues Common in Pediatric Patients With Immune Thrombocytopenia
Fatigue, emotional and behavioral symptoms, and executive functioning were found to be associated with quality of life but not with bleeding severity and platelet count.
Risk Score to Prevent Bleeding With Vitamin K Antagonists for Venous Thromboembolism
Researchers developed a risk score to assess risk for vitamin K antagonist-associated bleeding events in patients with venous thromboembolism.
Thrombosis Risk With Immune Thrombocytopenia
In multivariate analysis, history of atrial fibrillation and smoking were associated with risk for thrombosis in patients newly diagnosed with immune thrombocytopenia.
Immune Thrombocytopenia: Durable Responses Noted With Eltrombopag Plus Pulsed Dexamethasone
More than half of evaluable patients who received eltrombopag and pulsed dexamethasone achieved the study’s primary end point.
Splenomegaly May Be a Negative Prognostic Factor in Essential Thrombocythemia and Polycythemia Vera
Currently, splenomegaly is not included as a prognostic factor in major prognostic models of Philadelphia-negative myeloproliferative neoplasms.
Rivaroxaban for Children With Acute Venous Thromboembolism
Researchers assessed the efficacy of rivaroxaban in comparison with other standard anticoagulants in children with acute venous thromboembolism.
Time of Day for Taking Warfarin Does Not Matter
Morning or evening administration makes no difference on time outside target INR range
Peripherally Inserted Central Catheters May Increase Venous Thromboembolism Risk in Children
Researchers compared the incidence of venous thromboembolism between children with peripherally inserted central catheters and children with tunneled lines.
Bomedemstat Receives Fast Track Status for Essential Thrombocythemia
The FDA has granted Fast Track designation to bomedemstat (IMG-7289; Imago BioSciences) for the treatment of essential thrombocythemia, a myeloproliferative disorder characterized by high platelet counts.
- Loading...
Loading...
Next post in Thrombotic Disorders
Loading... 
Loading...